Moderna says Covid-19 vaccine shows 96% efficacy in teens in early data

06/05/2021 17:03:43 Society

Moderna's Covid-19 vaccine, mRNA-1273, has shown an efficacy of 96% among teens in early data, CEO Stéphane Bancel announced during an earnings call on Thursday.

Moderna's trial in teens, called the TeenCOVE study, includes people ages 12 to 17.

"We are pleased to report this morning an interim update to our TeenCOVE study," Bancel said. "An initial interim analysis of our Phase 2/3 TeenCOVE study of mRNA-1273 showed vaccine efficacy against Covid-19 of 96% and mRNA-1273 was generally well tolerated with no serious safety concerns identified to date."Moderna’s Covid-19 vaccine is currently authorized for use in people ages 18 and older.

News

20/05/2025 06:30:14

GEOCASE on Integration of Intelligence Service into State Security Service: "We urge "Georgian Dream" to refrain from taking this imprudent action"

05/05/2025 23:10:42

The U.S. House of Representatives has supported the "MEGOBAR Act"

24/04/2025 22:02:41

State Department: US has made clear the steps Georgia’s government can take to demonstrate it is serious about improving its relationship with US

24/03/2025 15:00:29

The investigative commission studying the activities of the "National Movement" government invited Mamuka Khazaradze and Badri Japaridze to the session

24/03/2025 14:54:19

The court found Temur Katamadze guilty of verbally insulting Nino Nadiradze and imposed a fine of 2,800 GEL on him

24/03/2025 14:46:40

The so-called Supreme Court of occupied Donetsk has sentenced Nadim Khmaladze, who is fighting in Ukraine, to 14 years in prison in absentia

შემოგვიერთდით

February

2021